OCTOBER 2021LIFE SCIENCES REVIEW6Unlike most industries in these extraordinarily challenging times, biotech is experiencing a high. Executives in many other sectors are becoming more pessimistic about the outlook for their businesses as the global pandemic continues to spread. But the search to understand and find treatment or preventive solutions to COVID-19 has focused intense government, media, and public attention on science and medicine, reinforcing the perception that biotech acquisitions and partnerships represent a good investment.With the research industry becoming more expansive, many scientists and field experts discover a lot of things discover conditions that are inherited because of genetics. The implications of these are healthcare can be more personalized and customized based on human DNA and some other genome characteristics. This paves the way for the production of a more personal kind of medicine, including procedural healthcare requirements.The areas studying the life sciences are continuously developing and evolving. Its collaborative nature also means that its discoveries are dependent on past and present learning. In 2022, biotech companies are expected to join forces and collaborate with other healthcare-related science organizations, so they can all together push the industry and aim for better results.In 2022, one of the continuing trends in biotech will be the continued improvement and development of drug research. The advent of smart technology will continue to allow the possibility of improving and assessing diagnosis and treatment using medications. Think along the lines of telehealth, where technology is leveraged to bridge time and space so patients no longer have to leave the comforts of their own home to get a thorough check-up.Looking forward, the combination of advances in biological science and accelerating developments in technology and artificial intelligence has the potential to take innovation to a new level. A recent report from the McKinsey Global Institute analyzed the profound economic and social impact of biological innovation and found that biomolecules, biosystems, biomachines, and biocomputing could collectively produce up to 60 percent of the physical inputs to the global economy. The applications of this "Bio Revolution" range from agriculture (such as the production of nonanimal meat) to energy and materials, and from consumer goods (such as multi-omics tailored diets) to a multitude of health applications.Let us know your thoughts.EDITORIALThe Beginning of the `Bio-Revolution'Copyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com October - 25 - 2021 02, Issue - 10 Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersRonald Donovan*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsSalesStephen Thomassales@lifesciencesreview.comDean WinchesterVictor Cruz
< Page 5 | Page 7 >